A PROSPECTIVE OBSERVATIONAL AND INTERVENTIONAL STUDY ON THE ROLE OF DOCTOR OF PHARMACY/CLINICAL PHARMACIST IN IDENTIFICATION, REPORTING AND MINIMIZATION OF DRUG-RELATED PROBLEMS IN PULMONARY AND CARDIOLOGY DEPARTMENTS OF ESI HOSPITAL
Objective: The present study aims at implementing the doctor of pharmacy services in the identification and reporting of drug-related problems in the in-patient units of cardiology and pulmonary medicine departments of ESI Hospital, Bangalore.
Methods: A prospective interventional study was conducted from September 2018 to March 2019. Determination and categorization of drug-related problems (DRPs) were performed by the pharmacist using the PCNE classification scheme for drug-related problems V5.01. The DRPs identified by the pharmacist were reported and interventions made were subsequently recorded.
Results: 180 drug-related problems were identified in the study, among which the major problems were drug-drug interactions (13.88%), followed by generic substitution (10%). The mean drug-related problem per patient was found to be 1.06. A total of 196 interventions were made by the clinical pharmacists among which, 109 (55.61%), 56 (28.57%), 17 (8.67%) interventions were at the prescriber, drug, patient levels, and 14 (7.14%) cases were the rest of interventions or activities. Distributions based on type and degree of acceptance of interventions showed that among 56 drug regimen change interventions proposed by the pharmacist, only 55.35% were accepted. The results further indicated that out of 68 monitoring required interventions made by the pharmacist, and among 17 cases that required counseling by the pharmacist in verbal, 77.94% and 88.36% of cases were accepted, respectively. Also, regarding the cases that required communication between the pharmacists and other healthcare professionals, 85.36% of a total of 41 samples and all of 14 adverse drug reporting cases made in a formal note form were accepted.
Conclusion: The clinical pharmacist’s/doctor of pharmacy professional’s timely interventions in the patient’s drug therapy is required to prevent or minimize the occurrence and the risk of DRP. Rational drug therapy and optimal medication safety can be achieved by clinical pharmacy services.
2. Molino Cde G, Carnevale RC, Rodrigues AT, Visacri MB, Moriel P, Mazzola PG. Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection. Ther Clin Risk Manag 2014;10:631-9.
3. Marc A, Adrian M. Adverse drug reactions: types and treatment options. Am Fam Physician 2003;68:1781-91.
4. Sarfaraz Mohammed, Poudel S, Fernance Laloo, Arjun Madhur, Rinson Robert, Mathew B. Assessment of drug-related problems in a tertiary care teaching hospital, India. Asian J Pharm Clin Res 2020;10:310-3.
5. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990;24:1093-7.
6. Malahat AR, Latha CD, KS Baloju D, Vijayalakshmi G. Study to evaluate severe ADRs in a tertiary care teaching hospital. Int J Curr Pharm Sci 2017;9:55-8.
7. ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy. Am J Health Syst Pharm 1995;52:417-9.
8. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21:247-54.
9. Ansari J. Drug interaction and pharmacist. J Young Pharm 2010;2:326-31.
10. Jith A, Kumar CT, Joy JS, P KS, R SK. A prospective study of drug-drug interactions and adverse drug reactions among stroke patients in a tertiary care hospital. Asian J Pharm Clin Res 2016;9:100-4.
11. Nikhithasri P, Ramya M, Kishore P. Assessment of medication errors in pediatric in-patient department of a private hospital. Int J Curr Pharm Sci 2017;9:70-5.
12. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
13. Akonoghrere Rita O, Arute John E, Akparobore Akpevwe. Impact of pharmaceutical care interventions on the quality of life of a group of hypertensive patients. UK J Pharm Biosci 2016;4:19-28.
14. Shareef J, Sandeep B, Shastry CS. Assessment of drug-related problems in patients with cardiovascular diseases in a tertiary care teaching hospital. J Pharm Care 2014;2:70-6.
15. Abdela OA, Bhagavathula AS, Getachew H, Kelifa Y. Risk factors for developing drug-related problems in patients with cardiovascular diseases attending Gondar University Hospital, Ethiopia. J Pharm Bioallied Sci 2016;8:289-95.
16. Carey MA, Card JW, Voltz JW. It's all about sex: gender, lung development, and lung disease. Trends Endocrinol Metab 2007;18:308?13.
17. Shevade Madhuragauri, Apte Komalkirti, Jadhav Sushma, Madas Sapna, Salvi Sundeep. What are the most common respiratory diseases encountered in clinical practice? Results of a pilot study in 737 Indian patients. Eur Respir J 2015;46:3864.
18. Niriayo Y, Kumela K, Kassa T, Angamo M. Drug therapy problems and contributing factors in the management of heart failure patients in Jimma University Specialized Hospital, Southwest Ethiopia. Plos One 2018;13:101-8.
19. Peterson C, Gustafsson M. Characterisation of drug-related problems and associated factors at a clinical pharmacist service-naïve hospital in Northern sweden. Drugs Real World Outcomes 2017;4:97-105.
20. Hooper R, Adam A, Kheir N. Pharmacist-documented interventions during the dispensing process in a primary health care facility in Qatar. Drug Healthc Patient Saf 2009;1:73-80.
This work is licensed under a Creative Commons Attribution 4.0 International License.